A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System

This study analyzed 1,331 cases of alopecia areata (AA) reported as adverse events in the FDA Adverse Events Reporting System, focusing on associated medications and patient demographics. Monoclonal antibodies were frequently linked to AA, with 6 out of the top 10 drugs associated with the condition. Males had higher odds of reporting AA when using adalimumab and dupilumab, while individuals aged 42-64 accounted for 46.7% of cases. Older females showed greater odds of developing AA compared to males. The study highlights a rise in AA cases and emphasizes the need for increased awareness and improved clinical outcomes.